Citadel Advisors
CNSP icon

Citadel Advisors’s CNS Pharmaceuticals CNSP Stock Holding History

Citadel Advisors’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-536
Closed -$38.8K – 14600
2024
Q4 		$38.8K Buy
+536
New +$38.1K ﹤0.01% 12638
2024
Q2 		– Sell
-3
Closed -$33K – 14375
2024
Q1 		$33K Buy
+3
New +$43.6K ﹤0.01% 12604
2023
Q2 		– Hold
0
– -$13.2K – 14440
2023
Q1 		– Hold
0
– – – 13372
2022
Q3 		– Hold
0
– -$6K – 12725
2022
Q2 		– Hold
0
– – – 12661
2022
Q1 		– Hold
0
– – – 13269
2021
Q4 		– Hold
0
– – – 13164
2021
Q3 		– Hold
0
– – – 13549
2021
Q2 		– Hold
0
– -$221K – 13732
2021
Q1 		– Hold
0
– – – 11503

Other funds holding CNSP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's CNSP Position: Q1 2025 in Review

Citadel Advisors sold out of CNS Pharmaceuticals (CNSP) in Q1 2025, closing a stake of 536 shares — an estimated $38.8K sold.

Citadel Advisors first reported a position in CNSP in Q1 2024 and held it in 2 quarters. The position peaked at $38.8K in Q4 2024. 7 funds tracked by Wall St. Rank hold CNSP as of Q1 2025.

  • Citadel Advisors reported no remaining CNS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 536 CNS Pharmaceuticals shares in Q1 2025, an estimated $38.8K.
  • Citadel Advisors first reported a position in CNS Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Citadel Advisors's CNS Pharmaceuticals position peaked at $38.8K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.